SRT 1460

CAS No. 925432-73-1

SRT 1460 ( SRT1460 )

Catalog No. M16630 CAS No. 925432-73-1

SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 50 Get Quote
5MG 71 Get Quote
10MG 106 Get Quote
25MG 159 Get Quote
50MG 239 Get Quote
100MG 357 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    SRT 1460
  • Note
    Research use only, not for human use.
  • Brief Description
    SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM.
  • Description
    SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol; improves insulin sensitivity, lowers plasma glucose, and increases mitochondrial capacity in obese mice model.
  • Synonyms
    SRT1460
  • Pathway
    Chromatin/Epigenetic
  • Target
    Sirtuin
  • Recptor
    Sirtuin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    925432-73-1
  • Formula Weight
    507.61
  • Molecular Formula
    C26H29N5O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1=CC=CC=C1C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=CC(OC)=C(OC)C(OC)=C5
  • Chemical Name
    3,4,5-Trimethoxy-N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Milne JC, et al. Nature. 2007 Nov 29;450(7170):712-6.
2. Pacholec M, et al. J Biol Chem. 2010 Mar 12;285(11):8340-51.
3. Hubbard BP, et al. Science. 2013 Mar 8;339(6124):1216-9.
4. Chini CC, et al. Clin Cancer Res. 2016 May 15;22(10):2496-507.
molnova catalog
related products
  • E1231

    E1231 (E-1231) is a small molecule SIRT1 activator with EC50 of 0.83 uM.

  • Pristimerin

    Pristimerin has anticancer activity, treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells.

  • AK-7

    A potent, selective and brain-permeable SIRT2 inhibitor with IC50 of 15.5 uM.